Drug Profile
Research programme: infection and cancer therapeutics - GlaxoSmithKline/Sun Pharmaceutical Industries
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Ranbaxy Laboratories
- Developer Sun Pharmaceutical Industries
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India
- 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries